Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment f

Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager.As previously communicated the OncoZenge strategy and focus...

Related Keywords

Stockholm ,Sweden ,Anna Asplind ,Program Manager ,Nilsson Clinical Research ,Clinical Research Organizations ,Oncozenge Certified Adviser Is Carnegie Investment Bank ,Astrazeneca ,Clinical Research Manager ,Mihai Andrei Florescu ,Stian Kildal ,Certified Adviser ,Carnegie Investment Bank ,